Dedicated to advancing physiologically relevant in vitro models, the 11th 3D Tissue Models Summit 2026 brings together leaders in organoids, spheroids, and complex co-culture systems.
This guide details how 3D tissue models are improving translatability across drug discovery and preclinical development.
Key themes include:
- Organoids and complex co-culture systems
- Disease modelling and translatability
- Integration into drug discovery pipelines
- Validation and scalability of 3D models
About Hanson Wade Group - 11th 3D Tissue Models Summit 2026
Tackling Complex In Vitro Model Validation, Balancing Scalability with Reproducibility & Cost to Ensure Translational Success Across Drug Discovery & Development
Regulatory and governmental momentum is forcing change, fast:
- The Senate have recently cleared the FDA Modernization Act 3.0
- The FDA have developed a roadmap that’s abandoning animal testing for mAbs
- NIH have closed the door on animal-only grants
- The UK join the plan to phase out animal testing, announced by the Science Minster Lord Vallance
Meanwhile, your pipelines are chasing novel targets that in vivo models can't predict.
The 11th 3D Tissue Models Summit is where the industry comes to solve this. As the only industry-led forum dedicated to advancing organoids, organ-on-chip, and MPS, you'll connect with scientists from AbbVie, Novartis, Vertex, and many more who are validating these models, securing regulatory buy-in, and making them work at scale. The shift is happening, so make sure your organization is ready.
Download the Event Guide
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.